Login
$ENTA
$11.20 +$0.53 (4.97%) After hours

$ENTA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 SCHEDULE 13G/A
29 Oct 2026 8-K: Other Events

As previously disclosed, Enanta Pharmaceuticals, Inc. (the “Company”) filed a patent infringement action in the Unified Patent Court (the “UPC”) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determi...

28 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

27 Oct 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition

Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027

10 Aug 2026 Form 4: Rottinghaus Scott T., Chief Medical Officer

Gave up 1,467 shares to cover exercise price or tax ($19.6K)

02 Jul 2026 8-K: Entry into a Material Definitive Agreement

Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), ...

02 Jul 2026 424B5
23 Jun 2026 8-K: Other Events

As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) relating to its suit against Pfizer Inc...

18 Jun 2026 8-K: Regulation FD Disclosure

Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research a...

13 May 2026 S-8
13 May 2026 10-Q
11 May 2026 8-K: Results of Operations and Financial Condition

Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026

26 Mar 2026 SCHEDULE 13G/A
26 Mar 2026 8-K: Other Events

As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), on February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. s...

13 Mar 2026 Form 4: Peterson Kristine, Director

Granted 20,000 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support